IL-23/TNF-α Bispecific Antibody JNJ-4804 Secures $500 Million Investment for Autoimmune Disease Development

Note:This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

According to the agreement, Royalty Pharma will2026 to 2027Cumulative Investment$500 million, for the advancement of drugs under research for autoimmune diseasesJNJ-4804Development.

JNJ-4804For aNovel Bispecific Antibody Therapy, can simultaneously blockInterleukin-23 (IL-23)AndTumor Necrosis Factor (TNF)Two complementary inflammatory signaling pathways contribute to the pathogenesis of chronic immune-mediated diseases.Synergistic Inhibition。

Pablo Legorreta, CEO and Chairman of the Board of Royalty Pharma"We are very pleased to collaborate with Johnson & Johnson to advance the clinical development of JNJ-4804."Royalty Pharma Has Rich Investment Experience in the Field of Immunology, early layout including TNF inhibitors in disease-modifying biologics. Johnson & Johnson is a recognized leader in the field of immunology, and we believe JNJ-4804 has significant therapeutic potential for patients with chronic immune-mediated diseases. This collaboration is another important opportunity to fulfill our commitment to partner with global biopharmaceutical companies." This product is Guselkumab/Golimumab (JNJ-78934804).

References:

PharmaCircle Data;

Moxie Pharma pharma.bcpmdata.com (formerly known as Pharma Data Cloud);

https://www.expresspharma.in；

http://www.marketscreener.com；

https://www.businesswire.com；

www1.hkexnews.hk/；

Etc.